News
TEM
54.96
-0.19%
-0.11
Tempus Q2 Earnings Call Highlights Data Growth and Pricing Upside
NASDAQ · 4h ago
Weekly Report: what happened at TEM last week (0803-0807)?
Weekly Report · 1d ago
Tempus AI (TEM) After CellCarta Deal And PRISM2 Validation Faces A Fresh Valuation Test
Simply Wall St · 2d ago
Why Tempus AI (TEM) Is Up 18.6% After Joining CellCarta’s CDx Commercialization Lab Network
Simply Wall St · 3d ago
Why Is Tempus AI Stock Surging on Friday?
Benzinga · 4d ago
Caris Life Sciences: Guidance Raised, Valuation Still Attractive
Seeking Alpha · 4d ago
Tempus AI added to CellCarta’s CDx commercialization lab network
TipRanks · 5d ago
CellCarta To Include Tempus In CDx Commercialization Lab Network As Network's Second Commercial Laboratory Partner, Enhancing Oncology Companion Diagnostics For Biopharma
Benzinga · 5d ago
The BioRevolution Has Accelerated
Seeking Alpha · 6d ago
Personalis says not providing guidance or conducting earnings call
TipRanks · 6d ago
Tempus AI Is Maintained at Neutral by Piper Sandler
Dow Jones · 08/04 14:51
Tempus AI Price Target Cut to $56.00/Share From $58.00 by Piper Sandler
Dow Jones · 08/04 14:51
Piper Sandler Maintains Neutral on Tempus AI, Lowers Price Target to $56
Benzinga · 08/04 14:41
Piper Sandler Keeps Their Hold Rating on Tempus AI, Inc. Class A (TEM)
TipRanks · 08/04 13:49
Tempus AI Announces Publication Of Study Results In 'Nature Medicine' That Demonstrate The PRISM2 Pathology Foundation Model's Ability To Perform Clinically Important Diagnostic Tasks
Benzinga · 08/04 12:36
Tempus AI announces study results of PRISM2
TipRanks · 08/04 12:36
Tempus AI price target lowered to $56 from $58 at Piper Sandler
TipRanks · 08/04 10:56
Tempus AI Price Target Cut to $70.00/Share From $80.00 by BTIG
Dow Jones · 08/03 18:16
Tempus AI Is Maintained at Buy by BTIG
Dow Jones · 08/03 18:16
BTIG Maintains Buy on Tempus AI, Lowers Price Target to $70
Benzinga · 08/03 18:06
More
Webull provides a variety of real-time TEM stock news. You can receive the latest news about Tempus AI through multiple platforms. This information may help you make smarter investment decisions.
About TEM
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.